The Effect of Non-Overlapping Somatic Mutations in BRAF, NRAS, NF1, or CKIT on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma.

Cancers (Basel) · 2024 · PMC10854687 · PMID 38339344

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Pretreatment LDH, TMB, and PDL1 expression did not reach statistical significance as predictive biomarkers for development of brain metastases. 4.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

The Effect of Non-Overlapping Somatic Mutations in &lt;i&gt;BRAF&lt;/i&gt;, &lt;i&gt;NRAS&lt;/i&gt;, &lt;i&gt;NF1&lt;/i&gt;, or &lt;i&gt;CKIT&lt;/i&gt; on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma.

The sentences

The Effect of Non-Overlapping Somatic Mutations in <i>BRAF</i>, <i>NRAS</i>, <i>NF1</i>, or <i>CKIT</i> on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma.